Lee Hartwell is the new director of the Fred Hutchinson Cancer Research Center ('the Hutch') in Seattle, Washington. It's hard to believe that this adroit and softspoken man was once a "tearaway" -cruising the streets of 1950s Los Angeles with his high school gang, and sporting a black wool jacket with a dragon emblem. Though there's still something of the maverick in him, he grew tired of the gang lifestyle in high school, and went on to fall in love with biology in college, becoming absorbed by the cell cycle and the genetics that control it.
His work at the University of Washington, where he has been for the past 30 years, has earned him a reputation as a 'scientist's scientist'; he is widely admired for his brilliant, if sometimes impenetrable, research. Hartwell was the first to demonstrate, in the 1960s, that the cell cycle in yeast cells is genetically controlled. He also documented the existence of cell-cycle checkpoints -control mechanisms that ensure a given stage in cell division has been completed before the next stage begins.
More recently, Hartwell has suggested a role for checkpoint defects and genetic instability in cancer progression, and has proposed how to exploit these defects to devise rational cancer therapies. "For over 30 years, a majority of the key insights into the cell cycle have been made by [him] ," according to Mark Groudine, director of the basic sciences division at the Hutch. Doug Koshland, a geneticist at the Carnegie Institute in Baltimore and former post-doc of Hartwell's, recalls him as a deep thinker. "You'd tell him something, and you would not necessarily get an immediate response -you might even think he hadn't been paying attention to you. Then three or four days later he'd come back and tell you what he thought. You could tell he'd thought really hard about the problem."
The yeast cell cycle work helped set the stage for an explosion in human cancer research when, in a 1987 article in Nature, Paul Nurse announced that the human homologue of the CDC2 genewhich encodes a protein kinase that is essential to the cell cycle in yeast -would function when transfected into yeast cells that lacked the gene. Soon others confirmed that many human homologues of yeast genes perform the same functions, and a wealth of information gleaned from yeast cells was suddenly directly applicable to the study of human cell division -and cancer. Though the discoveries were as much of a surprise to him as to the rest of the research world, in hindsight, Hartwell says they shouldn't have been. "The metabolic pathways are all the same, why shouldn't the [signal pathways that lead to cell division] be the same?"
The revelation that the yeast model had so much to offer caused great excitement, but Hartwell realized the time had come to move past these simplified systems. "I came to the conclusion that human biology would only become clearer through a real combination of three disciplines: basic science, clinical sciences, and the population sciences." A year ago, Hartwell joined the Hutch, to embark on what he calls his "sociological experiment." Dubbed by Hartwell the Interdivisional Research and Training Initiative, it called for meetings and retreats to bring researchers from these diverse disciplines together for a view of "the big picture" of cancer.
The approach made an impression on Ross Prentice, director of the public health division at the Hutch. "It was refreshing to me that a senior person with a very substantial reputation as a basic biological scientist was willing to move his base to [the Hutch] and commit half of his time to interdisciplinary research program development . . . as scientists we tend to have the knee-jerk reaction that whatever we don't know about can't be important, so it takes somebody with confidence to step out and endorse the groups and areas that they are not a part of," says Prentice.
Hartwell is now playing an even larger role. This month, he took over from the director of the past 16 years, Robert W. Day. Hartwell figures that the invitation to take over the directorship was a indication that the institution wanted to emphasize communication between the disciplines ". . . certainly, if they wanted a strong administrator, I don't have a track record [as one]," he says.
Many at the Hutch believe Hartwell's tenure will bring changes in the atmosphere and research directions. The molecular medicine division -dwarfed by the Center's larger public health, clinical research, and basic science divisions -seems especially likely to thrive, as the approach of its scientists seems tailormade to Hartwell's interdisciplinary vision.
Hartwell is ready to get stuck in: "The next thing to do is roll up our sleeves, and we'll make a real impact on cancer."
